国产新冠疫苗英文名字 (中英翻译对照和图片说明）_北京外宾旅游指南

Sinovac COVID-19 vaccine
北京科兴中维新冠疫苗

Four vaccines are currently approved for use in the EU: Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson. Another four are under "rolling review" for possible approval: Russia's Sputnik, China's Sinovac, Germany's CureVac and Novavax of the United States. (straitstimes.com/July 01, 2021)

Sinovac 北京科兴 (Image Credit: bnnbloomberg.ca)

Sinopharm COVID-19 vaccine （Beijing）
国药北京所新冠疫苗

Another vaccine developed by a Beijing-based institute linked to Sinopharm, which this month obtained emergency use approval by the World Health Organization (WHO), showed a 78.1% efficacy, the paper said. The readings were based on calculations over 142 symptomatic cases in a trial involving more than 40,000 participants, with 26 injected with the Wuhan unit's vaccine and 21 with the Beijing unit's shot, it said. （BBC/May 27, 2021)

国药北京 Sinopharm Beijing（Image Credit: India Today and WHO)

Sinopharm COVID-19 vaccine （Wuhan）
国药中生武汉公司新型冠状疫苗

A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8% effective against symptomatic COVID-19 at least two weeks after second injection, based on interim results, the peer-reviewed study published in the Journal of the American Medical Association showed on Wednesday. (reuters.com/May 27, 2021）

CanSinoBIO COVID-19 vaccine
康希诺生物新冠疫苗

CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company. This Chinese company has developed a COVID vaccine based on an adenovirus in partnership with the Chinese Academy of Military Medical Sciences. The adenovirus is unable to cause disease itself, but is used to deliver a coronavirus protein. （theconversation.com/）

CanSino Biologics 康希诺生物 (Image Credit: Getty Image/fortune.com)

Zifivax COVID-19 vaccine
安徽智飞新冠疫苗

Chinese-based company, Anhui Zhifei Longcom, has developed a protein subunit COVID-19 vaccine known as Zifivax COVID-19 vaccine. Subunit vaccines use a purified piece of the virus, a protein, to trigger an immune response. It has recently started phase 3 clinical trials. There hasn’t yet been any announcement or published report of the results of phase 1 and 2 trials. （theconversation.com/）

Indonesia has approved a COVID-19 vaccine produced by Chinese company Anhui Zhifei Longcom Biopharmaceutical for emergency use, the country's food and drug agency BPOM said on Thursday.

"Today, BPOM again announces that we have approved a COVID-19 vaccine product under the trade name Zifivax, which was developed with a recombinant protein sub-unit platform," BPOM's head Penny Lukito told a virtual press conference. (news.cgtn.com)